Nova Patents
EP1523982A3

Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders

Abstract

Compositions and methods of treating various disorders by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents including retinoids, hydroxyurea, and flavonoids. Intravesicle methods of treatment of cancers phenylacetate. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention. A product as a combined preparation of phenylacetate and a retinoid, hydroxyurea, or flavonid (or other mevalonate pathway inhibitor) for simultaneous, separate, or sequential use in treating a neoplastic condition in a subject. Methods of modulating lipid metabolism and/or reducing serum triglycerides in a subject using phenylacetate.

Term

Term ended

Projected expiry passed 12 October 2014, 12 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

Every citation, both ways

Citations
DocumentRelationOfficeCategoryCited duringRelevant claims
EP0069232A2CitesEuropean Patent Office (EPO)YSearch report1-6,60-64,69
W. NEISH: "Phenylacetic acid as a potential therapeutic Agent for the treatment of human cancer", EXPERIENTIA, vol. 27, 1971 - 1971, pages 860 - 861, XP002317232Non-patent––Search report–
S.R. BURZYNSKI: "Preclinical studies on Antineoplaston AS2-1 and Antineoplaston AS2-5", DRUGS EXP. CLIN. RES., vol. 12, 1986 - 1986, pages 11 - 16, XP002317233Non-patent––Search report–
Y. SHECHTER ET AL.: "Hydroxyphenyl acetate derivatives inhibit protein tyrosine kinase activity and proliferation in Nb2 rat lymphoma cells and insulin-induced lipogenesis in rat adipocytes", MOL. CELL. ENDOCRINOL., vol. 80, no. 1-3, 1991 - 1991, pages 183 - 192, XP002317234Non-patent––Search report–
D. SAMID ET AL.: "Phenylacetate: A novel nontoxic inducer of tumor cell differentiation", CANCER RES., vol. 52, no. 7, 1992 - 1992, pages 1988 - 1992, XP002317235Non-patent––Search report–
D. SAMID ET AL.: "Interferon in combination with antitumourigenic phenyl derivatives: potentiation of IFN alpha activity in-vitro", BR. J. HAEMATOL., vol. 79, 10 October 1991 (1991-10-10), pages 81 - 83, XP002317236Non-patent––Search report–
ABEMAYOR E ET AL: "Effects of retinoic acid on the in vivo growth of human neuroblastoma cells.", CANCER LETT (NETHERLANDS), NOV 19 1990, VOL. 55, NO. 1, PAGE(S) 1-5,, 1990, XP002317237Non-patent––Search report–
CINATL J ET AL: "In vitro differentiation of human neuroblastoma cells induced by sodium phenylacetate.", CANCER LETT (NETHERLANDS), JUN 15 1993, VOL. 70, NO. 1-2, PAGE(S) 15-24,, 1993 - 1993, XP002317238Non-patent––Search report–
GORSKI GK ET AL: "Synergistic inhibition of human rhabdomyosarcoma cells by sodium phenylacetate and Tretinoin [letter]", IN VITRO CELL DEV BIOL (UNITED STATES), MAR 1993, VOL. 29A (3 PT 1, PAGE(S) 189-91,, 1993, XP002317239Non-patent––Search report–
WADA R ET AL: "Effects of phenylacetate and its interaction with retinoic acid on human neuroblastoma differentiation", PROCEEDINGS OF THE AMERICAN ASSOC. FOR CANCER RESEARCH ANNUAL MEETING, vol. 35, March 1994 (1994-03-01), pages 419, XP002317240Non-patent––Search report–
LIU L ET AL: "Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate.", J INVEST DERMATOL (UNITED STATES), SEP 1994, VOL. 103, NO. 3, PAGE(S) 335-40,, 1994, XP002317241Non-patent––Search report–
WOOD C G ET AL: "Phenylacetate and retinoic acid act synergistically to promote cellular differentiation in the prostate cancer cell lines LNCaP", J. UROL., vol. 151, no. 5, May 1994 (1994-05-01), pages 491A, XP002317242Non-patent––Search report–